Compare PNR & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNR | NTRA |
|---|---|---|
| Founded | 1966 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 27.0B |
| IPO Year | N/A | 2015 |
| Metric | PNR | NTRA |
|---|---|---|
| Price | $104.44 | $229.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | $119.43 | ★ $238.20 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.93 | N/A |
| Revenue | ★ $4,128,399,999.00 | $2,116,676,000.00 |
| Revenue This Year | $2.97 | $33.18 |
| Revenue Next Year | $4.61 | $16.81 |
| P/E Ratio | $26.91 | ★ N/A |
| Revenue Growth | 0.83 | ★ 38.17 |
| 52 Week Low | $74.25 | $125.38 |
| 52 Week High | $113.95 | $246.90 |
| Indicator | PNR | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 52.01 |
| Support Level | $105.18 | $227.89 |
| Resistance Level | $106.11 | $237.04 |
| Average True Range (ATR) | 1.67 | 5.07 |
| MACD | 0.15 | -1.57 |
| Stochastic Oscillator | 29.51 | 49.47 |
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.